Use of noninvasive ventilation (NIV) and high flow nasal therapy (HFNT) after early extubation in chest trauma patients
Effect of sequential use of noninvasive ventilation (NIV) and high flow nasal therapy (HFNT) after early extubation on re-intubation rate in chest trauma patients recovering from hypoxemic acute respiratory failure: a single-center feasibility study
University of Palermo. Pocliclinico P. Giaccone
30 participants
Nov 24, 2017
Interventional
Conditions
Summary
Chest trauma is a common event and may lead to respiratory failure due to several mechanism such as lung contusion and rib fractures. The respiratory failure may create the need for intubation and mechanical ventilation and long stay in intensiva care unit. Non invasive ventilation is form of ventilation delivered by non invasive devices different from endotracheal tubes. It may help patients with respiratory failure, especially less severe forms. High flow nasal therapy is a form of respiratory support that uses high flow of oxygen-air mixture delivered via nasal cannulas. This therapy is useful in less severe forms of respiratory failure or to prevent its incidence or worsening. Rationale: The sequential use of Non invasive ventilation and High flow nasal therapy to facilitate discontinuation of mechanical ventilation in chest trauma patients with acute hypoxemic respiratory failure (hypoxemic ARF) has never been explored. Aim: This study will aim to assess the feasibility and safety of early extubation followed by immediate sequential use of non invasive ventilation and high flow nasal therapy.
Eligibility
Plain Language Summary
Simplified for easier understanding
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Sequential use of Non-invasive ventilation (NIV) and High flow nasal therapy. After inclusion, subjects will be treated successively first with a 2-h session of NIV then with a 1-h session of HFNT. Sequential application of these 2 treatments will be repeated to deliver 16h of NIV and 8 h of HFNT per day. The intervention will be administered by treating doctors. The intervention will be modulated as following: PEEP and Pressure support (PS) will be decreased by 2 cmH2O each if after 2 h on NIV when PaO2/FiO2 will exceeded 250mmHg till a minimum of 5 and 8 cmH2O. At this time patient will be switched to HFNT only. HFNT will be interrupted if at the end of the all the following occurred: pH >7.35, PaCO2 < 45mmHg and PaO2 > 70 mmHg, RR < 30 breaths/min, absence of dyspnoea, respiratory accessory muscles recruitment, and paradoxical abdominal motion during 30-min spontaneous breathing trial (SBT) with oxygen supplementation through a Venturi mask at a FiO2 of 0.35. The HFNT device (Optiflow, Fisher & Paykel Healthcare, Auckland, New Zealand) includes a venturi air-oxygen blender, which allows the accurate adjustment of FiO2 between 0.30 and 1.0 and delivery of gas flow up to 60 L/min through a heated humidifier (MR850, Fisher & Paykel Healthcare). The gas mixture will be routed through a circuit to the subject at a temperature of 37 degree Celtius and an absolute humidity of 44 mg/L via large-bore bi-nasal prongs. HFNC was initially administered at a gas flow of 60 L/min and a FIO2 of 1.0. FIO2 will be adjusted to maintain a SpO2 > 92%. NIV will be delivered to the subject in a semi recumbent position with a full-face mask (Fisher & Paykel Healthcare) connected to an ICU ventilator with a dedicated NIV mode (Evita 2 Dura-Drager Lubeck- Germany) equipped with a heated humidifier (Kendall Aerodyne Ultratherm). Full-face and oronasal masks will be utilized in rotation, to improve patient tolerance to NIV, as indicated. Subjects will be ventilated by NIV at the same support used before extubation. After that pressure support level will be targeted to an expired tidal volume of 7-8 mL/kg, PaCO2 < 45 mmHg, a pH >7.35 and RR< 30/breaths/min. PEEP will be adjusted to maintain PaO2/FiO2 ratio > 225. In the case PaO2/FiO2 will be less than 200 mmHg during NIV, PEEP will be increased to reach the target of 225 mmHg and left at that level for next three NIV rounds before reattempting its reduction. In the case PaO2/FiO2 will be less than 225 mmHg and at least 200 mmHg during HFNT NIV will be reassumed for 2 hours before restarting HFNT. Duration of the intervention: PEEP and PS will be decreased by 2 cmH2O each if after 2 hours on NIV when PaO2/FiO2 will exceeded 250mmHg till a minimum of 5 and 8 cmH2O. At this time patient will be switched to HFNT only. HFNT will be interrupted if at the end of the all the following parameters will occur: pH >7.35, PaCO2 < 45mmHg and PaO2 > 70 mmHg, RR < 30 breaths/min, absence of dyspnoea, respiratory accessory muscles recruitment, and paradoxical abdominal motion during 30-min spontaneous breathing trial (SBT) with oxygen supplementation through a Venturi mask at a FiO2 of 0.35.
Locations(1)
View Full Details on ANZCTR
For the most up-to-date information, visit the official listing.
ACTRN12616001727437